Dietary administration of high doses of pterostilbene and quercetin to mice is not toxic

Journal of Agricultural and Food Chemistry

Volumn 57, Issue 8, 2009, Pages 3180-3186

  Ruiz, M J ^a,b   Fernandez M ^a,b   Pico Y ^a,b   Manes J ^a,b   Asensi, M ^a,b   Carda, C ^a,b   Asensio, G ^a,b   Estrela, J M ^a,b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

28 day feeding study; Mice; Quercetin; Subchronic toxicity; T pterostibene

Indexed keywords

PTEROSTILBENE; QUERCETIN; STILBENE DERIVATIVE;

ANIMAL; ARTICLE; DIET; DRUG EFFECT; ERYTHROCYTE COUNT; FEMALE; HEMATOCRIT; MALE; MOUSE; SEXUAL DEVELOPMENT; WEIGHT GAIN;

ANIMALS; DIET; ERYTHROCYTE COUNT; FEMALE; HEMATOCRIT; MALE; MICE; QUERCETIN; SEX CHARACTERISTICS; STILBENES; WEIGHT GAIN;

MUS;

EID: 65349173645     PISSN: 00218561     EISSN: None     Source Type: Journal    
DOI: 10.1021/jf803579e     Document Type: Article

References (40)

1. Aherne, S. A.; O'Brien, N. M. Dietary flavonols: chemistry, food content, and metabolism. Nutrition 2002, 18, 75-81.
2. Eriund, I. Review of the flavonoids quercetin, hesperetin, and naringenin. Dietary sources, bioactivities, bioavailability, and epidemiology. Nutr. Res. (N.Y.) 2004, 24, 851-874.
3. Nakamura, Y.; Ishimitsu, S.; Tonogai, Y. Effects of quercetin and rutin on serum and hepatic lipid concentrations, fecal steroid excretion and serum antioxidant properties. J. Health Scì. 2000, 46, 229-240.
4. de Vries, J. H.; Hollman, P. C; van Amersfoort, I.; Olthof, M. R.; Katan, M. B. Red wine is a poor source of bioavailable flavonols in men. J. Nutr. 2001, 131, 745-748.
5. Hollman, P. C. H.; van Het Hof, K.; Tijburg, L. B. M.; Katan, M. B. Addition of milk does not affect the absorption of flavonols from tea in man. Free Radical Res. 2001, 34, 297-300.
6. 2-induced inhibition of gap junctional intercellular communication in rat liver cell line. Food Chem. Toxicol. 2009, 47, 404-409.
7. Wang, L.; Morris, M. E. Liquid chromatography-tandem mass spectroscopy assay for quercetin and conjugated quercetin metabolites in human plasma and urine. J. Chromatogr., B: Anal. Technol. Biomed. Life Sci. 2005, 821, 194-201.
8. Ferrer, P.; Asensi, M.; Segarra, R.; Ortega, A.; Benlloch, M.; Obrador, E.; Varea, M. T.; Asensio, G.; Jorda, L.; Estrela, J. M. Association between pterostilbene and quercetin inhibits metastatic activity of B16 melanoma. Neoplasia 2005, 7, 37-47.
9. Jang, M.; Cai, L.; Udeani, G. O.; Slowing, K. V.; Thomas, C. R; Beecher, C. W.; Fong, H. H; Farnsworth, N. R.; Kinghorn, A. D.; Mehta, R. G.; Moon, R. C.; Pezzuto, J. M. Cancer chemopre-ventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275, 218-220.
10. Pervaiz, S. Resveratrol: from grapevines to mammalian biology. FASEB J. 2003, 17, 1975-1985.
11. Rimando, A. M.; Nagmani, R.; Feller, D. R.; Yokoyama, W. Pterostilbene, a new agonist for the peroxisome proliferator-activated receptor alpha-isoform, lowers plasma lipoproteins and cholesterol in hypercholesterolemic hamsters. J. Agric. Food Chem. 2005, 53, 3403-3407.
12. Ross, J. A.; Kasum, C. M. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu. Rev. Nutr. 2002, 22, 19-34.
13. Asensi, M.; Medina, L; Ortega, A.; Carretero, J.; Bano, M. C.; Obrador, E.; Estrela, J. M. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radical Biol. Med. 2002, 33, 387-398.
14. Manickam, M.; Ramanathan, M.; Jahromi, M. A.; Chansouria, J. P.; Ray, A. B. Antihyperglycemic activity of phenolics from Pterocarpus marsupium. J. Nat. Prod. 1997, 60, 609-610.
15. Yamamoto, N; Moon, J. H; Tsushida, T.; Nagao, A; Terao, J. Inhibitory effect of quercetin metabolites and their related derivatives on copper ion-induced lipid peroxidation in human low-density lipoprotein. Arch. Biochem. Biophvs. 1999, 372, 347-354.
16. Thomasset, S. C.; Berry, D. P.; Garcea, G.; Marczylo, T.; Steward, W. P.; Gescher, A. J. Dietary polyphenolic phytochemicals-promising cancer chemopreventive agents in humans? A review of their clinical properties. Int. J. Cancer 2007, 120, 451-458.
17. Rietjens, I. M.; Boersma, M. G.; van der Woude, H.; Jeurissen, S. M.; Schutte, M. E.; Alink, G. M. Flavonoids and alkenylben-zenes: mechanisms of mutagenic action and carcinogenic risk. Mutat. Res. 2005, 574, 124-138.
18. Undeger, U.; Aydin, S.; Basaran, A. A.; Basaran, N. The modulating effects of quercetin and rutin on the mitomycin C induced DNA damage. Toxicol. Lett. 2004, 151, 143-149.
19. Hollman, P. C.; van Trijp, J. M.; Buysman, M. N; van der Gaag, M. S.; Mengelers, M. J.; de Vries, J. H; Katan, M. B. Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man. FEBS Lett. 1997, 418, 152-156.
20. Pan, Z.; Agarwal, A. K; Xu, T; Feng, Q.; Baerson, S. R.; Duke, S. O.; Rimando, A. M. Identification of molecular pathways affected by pterostilbene, a natural dimethylether analog of resveratrol. BMC Med. Genomics 2008, http://dx.doi.org/10.1186/1755-8794-l-7.
21. Rimando, A. M.; Cuendet, M.; Desmarchelier, C; Mehta, R. G; Pezzuto, J. M.; Duke, S. O. Cancer chemopreventive and antioxidant activities of pterostilbene, a naturally occurring analogue of resveratrol. J. Agric. Food Chem. 2002, 50, 3453-3457.
22. Pari, L.; Satheesh, M. A. Effect of pterostilbene on hepatic key enzymes of glucose metabolism in streptozotocin- and nicotina-mide-induced diabetic rats. Life Sci. 2006, 79, 641-645.
23. Hollman, P. C. H; de Vries, J. H. M.; van Leeuwen, S. D.; Mengelers, M. J. B.; Katan, M. B. Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am. J. Clin. Nutr. 1995, 62, 1276-1282.
24. Anturlikar, S. D.; Gopumadhavan, S.; Chauhan, B. L.; Mitra, S. K Effect of D-400, a herbal formulation, on blood sugar of normal and alloxan-induced diabetic rats. Indian J. Phvsiol. Pharmacol. 1995, 39, 95-100.
25. Remsberg, C. M.; Yanez, J. A.; Ohgami, Y.; Vega-Villa, K. R.; Rimando, A. M.; Davies, N. M. Pharmacometrics of pterostilbene: Preclinical pharmacokinetics and metabolism, anticancer, antiin-flammatory, antioxidant and analgesic activity. Phvtother. Res. 2008, 22, 169-179.
26. Satheesh, M. A.; Pari, L. Effect of pterostilbene on lipids and lipid profiles in streptozotocin-nicotinamide induced type 2 diabetes mellitus. J. Appl. Med. 2008, 6, 31-37.
27. Suh, N; Paul, S.; Hao, X. P.; Simi, B.; Xiao, H.; Rimando, A. M.; Reddy, B. S. Pterostilbene, an active constituent of blueberries, suppresses aberrant crypt foci formation in the azoxymethane-induced colon carcinogenesis model in rats. Clin. Cancer Res. 2007, 13, 350-355.
28. Lamson, D. W.; Brignall, M. S. Antioxidants and cancer III: quercetin. Altern. Med. Rev. 2000, 5, 196-208.
29. de Boer, V. C. J.; van Schothorst, E. M.; Dihal, A. A.; van der Woude, H.; Arts, I. C. W.; Rietjens, I. M. C. M.; Hollman, P. C. H; Keijer, J. Chronic quercetin exposure affects fatty acid catabolism in rat lung. Cell. Mol. Life Sci. 2006, 63, 2847-2858.
30. Gugler, R.; Leschik, M.; Dengler, H. J. Disposition of quercetin in man after single oral and intravenous doses. Fur. J. Clin. Pharmacol. 1975, 9, 229-234.
31. Baur, J. A.; Pearson, K. J.; Price, N. L.; Jamieson, H. A.; Lerin, C; Kalra, A.; Prabhu, V. V.; Allard, J. S.; Lopez-Lluch, G; Lewis, K; Pistell, P. J.; Poosala, S.; Becker, K. G.; Boss, O.; Gwinn, D.; Wang, M.; Ramaswamy, S.; Fishbein, K W.; Spencer, R. G.; Lakatta, E. G; Le Couteur, D.; Shaw, R. J.; Navas, P.; Puigserver, P.; Ingram, D. K; de Cabo, R.; Sinclair, D. A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444, 337-342.
32. NTP Technical Report (TR-409) on the toxicology and carcinogenesis studies of quercetin (Cas No. 117-39-5) in F344/N rats (feed study). NIH Publication No. 91-3140 (1991). U.S. Department of Health and Human Services, Public Health Service, National Toxicology Program, Research Triangle Park, NC.
33. Bjeldanes, L. F.; Chang, G W. Mutagenic activity of quercetin and related compounds. Science 1997, 197, 577-578.
34. www.orgsyn.org.
35. European Council Directive 86/609/EEC on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes.
36. o 407; OECD: Paris, France, 1995.
37. Reagan-Shaw, S.; Nihal, M.; Ahmad, N. Dose translation from animal to human studies revisited. FASEB J. 2007, 22, 659-661.
38. Juan, M. E.; Vinardell, M. P.; Planas, J. M. The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J. Nutr. 2002, 132, 257-260.
39. Ohmuma, M. Effects of isorhamnetin, rhamnetin, and quercetin on the concentrations of cholesterol and lipoperoxide in the serum and liver and on the blood and liver antioxidative enzyme activities of rats. Biosci. Biotechnol. Biochem. 1995, 59, 595-60.
40. Zúñiga, J. M.; Marí, J. A. T; Milocco, S. N; Piñeiro González, R. Ciencia y tecnología en protección y experimentación animal; McGraw-Hill Interamerica: Madrid, 2001; p 27.